These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1678271)

  • 1. Pharmacokinetics and pharmacodynamics of a new transdermal delivery system for bopindolol.
    Drewe J; Meier R; Timonen U; Thumshirn M; Munzer J; Kissel T; Gyr K
    Br J Clin Pharmacol; 1991 Jun; 31(6):671-6. PubMed ID: 1678271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics after a single oral dose of bopindolol in patients with cirrhosis.
    Wensing G; Branch RA; Humbert H; Ohnhaus EE; Kirch W
    Eur J Clin Pharmacol; 1990; 39(6):569-72. PubMed ID: 1982762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Human pharmacologic studies on transdermal administration of mepindolol. Pharmacodynamic and orienting pharmacokinetics].
    Liedtke RK; Chen LS; Mangold B; Haase W
    Arzneimittelforschung; 1989 Nov; 39(11A):1501-4. PubMed ID: 2576199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of renal impairment on the pharmacokinetics and metabolism of bopindolol.
    MacDonald NJ; Grant AC; Rodger RS; Meredith PA; Elliott HL
    Br J Clin Pharmacol; 1991 Jun; 31(6):697-700. PubMed ID: 1678272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol.
    Aellig WH; Nüesch E; Engel G; Grevel J; Niederberger W; Rosenthaler J
    Br J Clin Pharmacol; 1986 Jan; 21(1):45-51. PubMed ID: 2868747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bopindolol for the treatment of chronic stable angina pectoris--a clinical study of the relationship between dose and effect.
    Holmes D; Fryda-Kaurimsky Z; Krueger K
    Cardiology; 1990; 77(6):459-65. PubMed ID: 1981493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal delivery of mepindolol and propranolol in normal man. 2nd communication: pharmacokinetic and neuro-endocrine aspects.
    de Mey C; Meineke I; Enterling D; Rehbock C; Osterwald H
    Arzneimittelforschung; 1989 Nov; 39(11A):1508-12. PubMed ID: 2576201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute and long-term antihypertensive effect of bopindolol once daily or once weekly.
    Andersson O; Hedner T; Nyberg G
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S74-6. PubMed ID: 2439826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind comparison of once-daily bopindolol and atenolol for mild-to-moderate hypertension.
    Colnago R; Meregalli M; Turri D; Nazzari M; Fiorella G; Guffanti EE; Mazzola C
    Int J Clin Pharmacol Ther Toxicol; 1987 Jun; 25(6):347-52. PubMed ID: 2887520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of mepindolol sulphate.
    Bonelli J; Hitzenberger G; Krause W; Wendt H; Speck U
    Int J Clin Pharmacol Ther Toxicol; 1980 Apr; 18(4):169-76. PubMed ID: 6103882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological experiments in healthy volunteers with bopindolol, a long-acting beta-adrenoceptor blocking drug with partial agonist activity.
    Aellig WH
    Br J Clin Pharmacol; 1985 Jun; 19(6):775-81. PubMed ID: 2862891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal delivery of mepindolol and propranolol in normal man. 1st communication: study design, clinical and pharmacodynamic aspects.
    de Mey C; Enterling D; Ederhof M; Wesche H; Osterwald H
    Arzneimittelforschung; 1989 Nov; 39(11A):1505-8. PubMed ID: 2576200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bopindolol in the treatment of moderate hypertension: a dose-response study.
    Moleur P; Peyrieux JC; Luciani J; David D; Boissel JP
    Fundam Clin Pharmacol; 1988; 2(5):431-40. PubMed ID: 2906897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.
    Harron DW; Goa KL; Langtry HD
    Drugs; 1991 Jan; 41(1):130-49. PubMed ID: 1706984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Withdrawal phenomena after atenolol and bopindolol: haemodynamic responses in healthy volunteers.
    Walden RJ; Tomlinson B; Graham B; Liu JB; Prichard BN
    Br J Clin Pharmacol; 1990 Oct; 30(4):557-65. PubMed ID: 1981318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiohemodynamic effects of bopindolol in normotensive conscious dogs. A comparative study with pindolol.
    Ishibashi T; Mitomi A; Tatebe S; Imai S
    Arzneimittelforschung; 1989 Apr; 39(4):454-7. PubMed ID: 2568836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady state pharmacokinetics of hydrolysed bopindolol in young and elderly men.
    Holmes D; Nuesch E; Houle JM; Rosenthaler J
    Eur J Clin Pharmacol; 1991; 41(2):175-8. PubMed ID: 1683836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bopindolol, a new long-acting beta-adrenoceptor antagonist--a randomized comparison against propranolol in hypertensive patients.
    Kirch W; Axthelm T
    Int J Clin Pharmacol Res; 1983; 3(2):89-93. PubMed ID: 6148312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bopindolol in chronic stable angina pectoris: duration and extent of antianginal action.
    Carboni GP; Scardovi AB; D'Ermo M; Prati PL
    Br J Clin Pharmacol; 1991 Dec; 32(6):755-7. PubMed ID: 1685090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Withdrawal of the long-acting beta blocker bopindolol is not associated with beta-adrenoceptor supersensitivity.
    Bolli P; Amann FW; Müller FB; Meyer B; Burckhardt D; Bühler FR
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S64-9. PubMed ID: 2439824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.